TrialScope Supports Moderna for Diversity Enrollment in Moderna’s Phase 3 Study of its COVID-19 Vaccine

JERSEY CITY, N.J.–(BUSINESS WIRE)–Fulfilling a commitment to diversity and inclusion in the Phase 3 COVE Study of the Moderna COVID-19 Vaccine, Moderna enlisted the help of TrialScope, the global leader in clinical trial disclosure and transparency technology, for patient recruitment. Moderna utilized TrialScope Connect, an industry-first patient referral collective that connects sponsors and clinical trial recruitment partners to rapidly find, screen and enroll clinical trial participants.

In October 2020, Moderna completed recruitment of more than 30,000 participants in the Phase 3 study of its COVID-19 Vaccine, utilizing TrialScope Connect’s platform in the final enrollment period to ensure inclusion of participants…